Navigation Links
Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Date:1/18/2011

," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements, and are based on Cadence's current beliefs and expectations. Such statements include, without limitation, statements regarding: the commercial launch of OFIRMEV; the anticipated U.S. market opportunity for IV acetaminophen; the ability of OFIRMEV to fill unmet medical needs and achieve formulary and market acceptance; and our strategy for building a long-term hospital pain franchise. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Actual future results may differ materially from our current expectations due to the risks and uncertainties inherent in Cadence's business. These risks include our dependence on the successful commercialization of OFIRMEV; the risk that delays in commercially launching or achieving formulary acceptance for OFIRMEV at a substantial number of targeted accounts would enable competitors to further entrench their products and decrease the market potential for OFIRMEV; our ability to ensure an adequate and continued supply of OFIRMEV to successfully launch commercial sales or meet anticipated market demand; OFIRMEV remains subject to substantial, ongoing regulatory requirements; our ability to comply with the terms of our loan agreement; the potential for an event of default under our loan agreement, and the corresponding risk of acceleration of repayment and potential foreclosure on the assets pledged to secure the line of credit; the potential that we may be required to file a lawsuit to defend our patent rights or regulatory exclusivities from challenges by companies seeking to market generic versions of intravenous acetaminophen; our ability to successfully enforce our intellectual property rights and defend our patents; the impact of healthcare reform legislation; the potential that we will require substantial additional funding in order to successfully commer
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cadence Pharmaceuticals Announces FDA Approval of OFIRMEV™ (acetaminophen) injection for the Management of Pain and Fever
2. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
3. Cadence Pharmaceuticals to Present at Two Investment Conferences During the Month of September 2009
4. Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results
5. Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
6. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
7. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
9. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2014)... 2014 The world-leading UV ... Kim, http://www.seoulviosys.com ) announced on September ... for the first time in the world. ... specific energy which deliver germicidal/pollutant-decomposing performance for ... food preservation applications. , The air purifier ...
(Date:9/2/2014)... , Sept. 2, 2014 Reportbuyer.com has ... Human Reproductive Technologies: Products and Global Markets ... AND OBJECTIVES The objective of the study ... the market for reproductive technologies and products. Markets ... The products in some markets are mature, while ...
(Date:9/2/2014)... 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 Market Research ... Market Research Report on Global Ammonium Acetate Industry" ... - http://photos.prnewswire.com/prnh/20140902/141873 2014 ... is a professional and in-depth research report on ... Bicarbonate market. The report introduces Sodium Bicarbonate basic ...
(Date:9/2/2014)... Little Company of Mary Hospital in Evergreen Park, IL, ... Pavilion patient tower, which included the selection of 500 ... nurse’s lounge near the maternity ward. Established ... $180 million, four-year Campus Transformation project is culminating in ... Pavilion tower to the North Pavilion, as well as ...
Breaking Biology Technology:Human Reproductive Technologies: Products and Global Markets 2Human Reproductive Technologies: Products and Global Markets 3Human Reproductive Technologies: Products and Global Markets 4Human Reproductive Technologies: Products and Global Markets 5Human Reproductive Technologies: Products and Global Markets 6Human Reproductive Technologies: Products and Global Markets 7Human Reproductive Technologies: Products and Global Markets 8Human Reproductive Technologies: Products and Global Markets 9Human Reproductive Technologies: Products and Global Markets 10Human Reproductive Technologies: Products and Global Markets 11Human Reproductive Technologies: Products and Global Markets 12Human Reproductive Technologies: Products and Global Markets 13Human Reproductive Technologies: Products and Global Markets 14Human Reproductive Technologies: Products and Global Markets 15Human Reproductive Technologies: Products and Global Markets 16Human Reproductive Technologies: Products and Global Markets 17Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 2Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 3Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 4Sodium Bicarbonate Market & Ammonium Acetate Industry: China & Global Analysis 5Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 2Tufftec® Lockers from Scranton Products Selected by Little Company of Mary Hospital Near Chicago to Create an Uplifting Environment 3
... blood cells can clog arteries. Source: National Institutes of Health. ... , a gene therapy researcher, announced on Wednesday that it ... Research grant from the National Institutes of Health. , ,The ... for the treatment of anemia, a blood disorder that kills ...
... has been tested on lab mice with no apparent ... at a recent conference. Information supporting this conclusion was ... ,Strong was optimistic of the molecules ability to inhibit ... treatments, the companys proprietary EVade Ribonucleases are effective at ...
... up 31 percent for quarter ConjuGon CEO to ... Canadian cancer drug Wisconsin DOA buys Seritis software ... Web site GE Healthcare profits up ... 31 percent from the same quarter last year, the company has ...
Cached Biology Technology:Mirus receives $1.26 million SBIR grant to combat anemia 2Cancer treatment advances as trials show no harm to mice 2Tech Digest: whats moving in the Midwest 2Tech Digest: whats moving in the Midwest 3
(Date:9/2/2014)... rates between indigenous and non-indigenous women in Queensland, Australia, ... of stillbirth due to preventable causes, find researchers in ... BJOG: An International Journal of Obstetrics and Gynaecology ... from the Queensland Perinatal Data Collection and looked at ... to assess the differences in stillbirth rates over time ...
(Date:9/2/2014)... rupture through a U.S. suburb , Observations and ... in the hours and days after the August 24 ... the earthquake caused so much damage in the region, ... hosted by the American Geophysical Union. , ... Next Places to Direct Our Curiosity , Selecting ...
(Date:9/2/2014)... will present the prestigious Parker/Gentry Award to Mr. Rhett ... conservation awareness. The Parker/Gentry Award is given annually by ... organization whose efforts have had a significant impact on ... can serve as a model to others. , Rhett ... and conservation news website that draws more than 2 ...
Breaking Biology News(10 mins):Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 2Stillbirth gap closing between indigenous and non-indigenous women, shows Australian study 3This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2
... you ever met a cat that doesn't go crazy over ... the world don't respond to it at all, according to ... of Chemical & Engineering News, the weekly newsmagazine published by ... Catnip sensitivity is inherited, says Carolyn M. McDaniel, a veterinarian ...
... Florida researchers say they are a step closer to ... cancers before symptoms become apparent. , The findings, currently ... Sciences, involve introducing molecularly engineered strands of DNA into ... burst after they adhere to cancer proteins. , ...
... the gene responsible for controlling a first key step in ... in the journal Nature tomorrow (Thursday 27 October 2005). , ... take place once a sperm enters an egg, giving it ... reproducing animals. , The absence or mutation of this gene ...
Cached Biology News:Many cats unaffected by catnip, C&EN reports 2Scientists closer to new cancer detection method 2Scientists closer to new cancer detection method 3Scientists unpick genetics of first 15 minutes of life 2
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Request Info...
... Reverse Transcriptase (AMV RT) catalyzes the polymerization ... RNA:DNA hybrids (1). It requires a primer ... primers) as well as Mg2+ or Mn2+. ... activity. Both nonionic detergents and sulfhydryl compounds ...
Request Info...
Biology Products: